Literature DB >> 11544285

Cutting edge: the spirochetemia of murine relapsing fever is cleared by complement-independent bactericidal antibodies.

S E Connolly1, J L Benach.   

Abstract

Abs are the major effectors of host defense against infections with BORRELIA: Bactericidal murine mAbs and their Fabs destroy B. burgdorferi, the agent of Lyme disease, and relapsing fever Borrelia in the absence of complement. These in vitro observations led to the expansion of a search for functionally similar Abs in vivo. In this study, we demonstrate that functionally unique IgM Abs develop in vivo and are responsible for the elimination of spirochetemia in murine models of relapsing fever, without the assistance of complement. Mice deficient in the fifth or third component of complement can clear the spirochetemia, whereas B cell-deficient mice cannot. The B cell-deficient mice developed spirochetemia that was an order of magnitude higher and persisted for a longer period of time in comparison to the wild-type mice. Additionally, B cell-deficient mice passively immunized with immune IgM and with immune serum were protected from challenge.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544285     DOI: 10.4049/jimmunol.167.6.3029

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Characteristics of Borrelia hermsii infection in human hematopoietic stem cell-engrafted mice mirror those of human relapsing fever.

Authors:  Raja Vuyyuru; Hongqi Liu; Tim Manser; Kishore R Alugupalli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  B1b lymphocyte-derived antibodies control Borrelia hermsii independent of Fcα/μ receptor and in the absence of host cell contact.

Authors:  Matthew J Colombo; David Abraham; Akira Shibuya; Kishore R Alugupalli
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 3.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

4.  Hypercholesterolemia and ApoE deficiency result in severe infection with Lyme disease and relapsing-fever Borrelia.

Authors:  Alvaro Toledo; Javier D Monzón; James L Coleman; Juan C Garcia-Monco; Jorge L Benach
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

Review 5.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Relapsing fever spirochetes Borrelia recurrentis and B. duttonii acquire complement regulators C4b-binding protein and factor H.

Authors:  T Meri; S J Cutler; A M Blom; S Meri; T S Jokiranta
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae.

Authors:  Harald Gelderblom; Jens Schmidt; Diana Londoño; Yunhong Bai; Jacqueline Quandt; Ron Hornung; Adriana Marques; Roland Martin; Diego Cadavid
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

8.  Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice.

Authors:  Eric Yager; Constantine Bitsaktsis; Bisweswar Nandi; Jere W McBride; Gary Winslow
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

9.  Immunological Responses to the Relapsing Fever Spirochete Borrelia turicatae in Infected Rhesus Macaques: Implications for Pathogenesis and Diagnosis.

Authors:  Monica E Embers; Aparna Krishnavajhala; Brittany A Armstrong; Michael W Curtis; Bapi Pahar; Hannah K Wilder; Michael S Allen; Paul A Beare; Nicole R Hasenkampf; Job E Lopez
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

10.  Adenoviral delivery of interleukin-10 fails to attenuate experimental Lyme disease.

Authors:  Charles R Brown; Annie Y-C Lai; Steven T Callen; Victoria A Blaho; Jennifer M Hughes; William J Mitchell
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.